

INDEX

I. INTRODUCTION	1
1. CANCER	2
1.1. CONCEPT.....	2
1.2. MOLECULAR BASES OF CANCER	2
2. LUNG CANCER	5
2.1. EPIDEMIOLOGY.....	5
2.2. ETIOLOGY.....	6
2.3. DIAGNOSIS AND PROGNOSIS.....	7
2.4. HISTOLOGICAL CLASSIFICATION	9
2.5. MOLECULAR PROFILE	10
2.6. MOLECULAR TARGETS AND TARGETED THERAPIES	11
2.7. CURRENT THERAPEUTIC APPROACHES IN NSCLC.....	13
3. CANCER STEM CELLS.....	16
3.1. TUMOR HETEROGENEITY.....	16
4. LUNG TUMOR MICROENVIRONMENT (TME)	19
4.1. THE IMMUNOLOGY OF TME.....	19
4.2. TUMOR CELL-MEDIATED IMMUNOSUPPRESSION	22
4.2.1. IMMUNE CHECKPOINTS	23
4.2.2. IMMUNOSUPPRESSIVE FACTORS	24
5. TUMORSPHERES: A 3D MODEL TO STUDY TME.....	25
6. BIOMARKERS IN LUNG CANCER. ROLE OF LIQUID BIOPSY	27
6.1. THE STATUS IN EARLY STAGES.....	27
6.2. THE STATUS IN ADVANCED STAGES	30
6.2.1. CIRCULATING BIOMARKERS	32
II. OBJECTIVES.....	35
III. MATERIALS & METHODS.....	37
1. STUDY DESIGN.....	38
2. MATERIALS.....	39
2.1. COHORTS AND SAMPLES INCLUDED IN THE STUDY	39
2.1.1. CONTROL GROUP.....	39
2.1.2. BLOOD FROM EARLY-STAGE NON-SMALL CELL LUNG CARCINOMA TEST COHORT	39
2.1.3. VALIDATION COHORT FROM TCGA.....	40
2.1.4. TISSUE FROM EARLY-STAGE NON-SMALL CELL LUNG CARCINOMA PATIENTS	40
2.1.5. BLOOD FROM ADVANCED-STAGE NSCLC COHORT	40
2.1.6. EXPLORATORY ENDPOINTS AND PATIENTS EVALUATION	41
2.2. <i>IN VITRO</i> CELL CULTURES.....	42

2.2.1.	PATIENT DERIVED LUNG CANCER CELL CULTURES.....	42
2.3.	CELL LINES.....	43
3.	METHODS.....	44
3.1.	ISOLATION OF EXTRACELULLAR VESICLES FROM CELL CULTURES	44
3.2.	PBMCS CULTURE.....	45
3.3.	CO-CULTURES CONDITIONS.....	45
3.4.	NUCLEIC ACID ANALYSIS.....	45
3.4.1.	RNA AND DNA ISOLATION	45
3.4.2.	DETERMINATION OF THE MUTATIONAL STATUS.....	46
3.4.3.	QUANTIFICATION OF GENE EXPRESSION	46
3.4.3.1.	REVERSE TRANSCRIPTION.....	46
3.4.3.2.	QUANTITATIVE REAL TIME PCR.....	47
3.5.	PROTEIN ANALYSIS	49
3.5.1.	IMMUNOASSAY.....	50
3.5.2.	IMMUNOBLOTTING.....	51
3.5.3.	FLOW CYTOMETRY	53
3.5.4.	IMMUNOFLUORESCENCE.....	54
3.6.	CIBERSORTX TOOL	54
3.7.	STATISTICAL ANALYSIS.....	56

IV. RESULTS & DISCUSSION 58

CHAPTER I. EXPLORATORY PHASE: *IN VITRO* STUDIES ON IMMUNE-MEDIATORS59

1.	<i>IN VITRO</i> MODELS: ADHERENT AND TUMORSPHERES CELL CULTURES.....	59
2.	GENE EXPRESSION ANALYSIS OF IMMUNOREGULATORY GENES.....	61
3.	PROTEIN SECRETION ANALYSIS OF IMMUNE-MEDIATORS.....	66
4.	DEEPING IN THE STUDY OF GALECTIN-3	69
4.1.	FLOW CYTOMETRY ANALYSIS	72
4.2.	IMMUNOFLUORESCENCE	74
4.3.	CORRELATION OF LGALS3 AND LGALS3BP	76
4.4.	ANALYSIS OF LGALS3 EXPRESSION IN EXTRACELLULAR VESICLES.	77
4.5.	GALECTIN-3 ANS ITS RELATIONSHIP WITH IMMUNE CELLS.	79
4.5.1.	<i>IN VITRO</i> APPROACH.....	80
4.5.2.	A STRATEGY BASED ON FORMALIN-FIXED PARAFFIN-EMBEDDED SAMPLES FROM HGUV COHORT	83
4.5.3.	A STRATEGY BASED ON CIBERSOTX TOOL WITH TCGA DATABASE	86

CHAPTER II. TRANSLATIONAL PHASE: STUDY OF IMMUNE-MEDIATORS BIOMARKERS.89

A) STUDY OF BIOMARKERS IN EARLY-STAGE NSCLC FROM CHGUV (TEST COHORT).....89

1.	CLINICOPATHOLOGICAL VARIABLES.....	89
2.	INDIVIDUAL SOLUBLE BIOMARKERS.....	95
2.1.	BIOMARKERS WITH DIAGNOSTIC VALUE.....	95

2.2.	BIOMARKERS WITH PROGNOSTIC VALUE.....	98
3.	MULTIVARIATE ANALYSIS.....	101
B)	VALIDATION STUDY: TCGA EARLY-STAGE NSCLC COHORT (VALIDATION COHORT)	103
1.	CLINICOPATHOLOGICAL VARIABLES.....	103
2.	INDIVIDUALS BIOMARKERS.....	108
3.	MULTIVARIATE ANALYSIS.....	109
C)	STUDY OF BIOMARKERS IN ADVANCED-STAGE NSCLC COHORT FROM HGUV	110
1.	CLINICOPATHOLOGICAL VARIABLES.....	110
2.	INDIVIDUALS SOLUBLE BIOMARKERS.....	115
2.1.	BIOMARKERS WITH DIAGNOSTIC VALUE.....	115
2.2.	BIOMARKERS THAT PREDICT RESPONSE TO IMMUNOTHERAPY.....	117
2.3.	BIOMARKERS WITH PROGNOSTIC VALUE.....	126
3.	MULTIVARIATE ANALYSIS.....	134
	INTEGRATION OF RESULTS CHAPTER I AND CHAPTER II	137
V.	CONCLUSIONS	142
VI.	REFERENCES	145
VII.	APPENDICES	198
1.	SUPPLEMENTARY MATERIAL.....	199
2.	APPROVAL FROM THE INSTITUTIONAL ETHICAL REVIEW BOARD.....	202
3.	FUNDING	203
4.	NATIONAL AND INTERNATIONAL CONGRESS COMUNICATIONS.....	203
5.	PUBLICATIONS.....	207
6.	AWARDS.....	209